Pietro A. Canetta, MD, illustrates how treating patients with IgA nephropathy is an exciting opportunity as treatment options have greatly expanded in recent decades. Today, FDA-approved drugs are available, with more on the horizon, providing better and varied choices than ever before.
However, as Dr Canetta notes, this progress brings new challenges, requiring a commitment to staying informed through literature, conferences, and consultation with colleagues specializing in glomerular disease. Success lies in embracing new treatments, seeking expert advice when needed, and continuously learning about the evolving landscape to enhance patient care.
